---
title: "In Vitro Cytokine Release Assays: Formats, Interpretation, and Limits"
description: "How in vitro cytokine release assays (CRA) support first-in-human safety for immunomodulatory biologics: formats, readouts, controls, and how to read results."
image: https://www.crystalbiosolutions.com/hubfs/Microplate%20Inspection%20for%20Customized%20Assay%20Analysis.webp
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

Nov 22, 2026

# In Vitro Cytokine Release Assays: Formats, Interpretation, and Limits

How in vitro cytokine release assays (CRA) support first-in-human safety for immunomodulatory biologics: formats, readouts, controls, and how to read results.

![In Vitro Cytokine Release Assays: Formats, Interpretation, and Limits](https://www.crystalbiosolutions.com/hubfs/Microplate%20Inspection%20for%20Customized%20Assay%20Analysis.webp)\\

Immunomodulatory drugs have been highly successful in inflammation, autoimmunity, transplantation, and oncology. Their strong biological activity can also trigger severe, sustained systemic cytokine release, known as a "cytokine storm." Cytokine storm and cytokine release syndrome (CRS) are life-threatening systemic inflammatory syndromes with elevated circulating cytokines and excessive immune cell activation. In vitro cytokine release assays (CRA) help identify this hazard before first-in-human (FIH) dosing.

## Lessons from OKT3 and TGN1412

The classic example is OKT3, a monoclonal antibody against the CD3 chain of the T-cell receptor complex. OKT3 induces high levels of TNF-α, IFN-γ, and IL-2, key pro-inflammatory cytokines that cause capillary leak, leukocyte sequestration, flu-like symptoms, and more \[1\]. With OKT3, T cells are clearly the source. Other antibodies, such as CAMPATH-1 or rituximab, do not activate T cells directly but can still cause cytokine release in the clinic, likely by cross-linking Fc receptors on other cytokine-secreting cells such as NK cells.

Understanding grew considerably after the TGN1412 trial, in which a cytokine storm caused multi-organ failure in healthy volunteers \[4\]. Since then, many groups have explored CRA formats to predict cytokine release and support FIH studies \[5–8\]. China's CDE immunogenicity guideline (March 2021) also states that, for immunomodulators, nonclinical evaluation should integrate all available in vivo and in vitro data, and that the cytokines measured should reflect the expected mechanism of cytokine release and the drug's clinical safety concerns.

## What CRA can and cannot do

Today, CRA is mainly a hazard identification tool. It does not support quantitative risk estimates, such as converting an effective in vitro concentration into an FIH dose. CRA can be used to rank several antibodies against the same target by potential risk, and it can provide mechanistic insight into cytokine release in humans, which helps define risks and mitigation strategies.

Whether a CRA is needed depends on how the product interacts with the immune system. Adjuvants, immunomodulators, and some monoclonal antibodies are typical candidates. Products that bind membrane-bound antigens or receptors are more likely to induce cytokine release than those that bind soluble molecules. Off-target effects, mechanism of action (for example ADCC or CDC), Fc affinity, and specificity should all shape the assay design. T-cell-mediated responses tend to be easier to predict than Fc-mediated effects such as ADCC.

## Choosing an assay format

Formats range from simple test systems to complex co-culture models that try to mimic the in vivo environment. Data from more than one format may be needed to show whether a drug triggers unexpected cytokine secretion. Products with a mechanism similar to TGN1412 can be assessed with solid-phase methods \[5, 6\]. Because each molecule works differently, the format has to fit its mechanism; current evidence is not sufficient to recommend a specific format for each target class. For monoclonal antibodies, the antibody can be presented in solution, dry-coated onto the plate, or captured indirectly through an anti-Fc antibody.

Human whole blood and peripheral blood mononuclear cells (PBMC) partly compensate for species differences that keep animal models from reproducing human immune activation. When the target is patient-specific, patient cells are the right source, but they are hard to obtain.

PBMC usually give a stronger cytokine response than whole blood. PBMC are not always better, however, because they lack some factors such as complement. Some studies use co-culture systems, for example PBMC with endothelial cells.

## Readouts and controls

- **Cytokines:** IL-2, IFN-γ, TNF-α, and IL-6 are usually the most relevant to harm. Add others based on the mechanism of action.
- **Platform:** multiplex immunoassays, such as electrochemiluminescence panels on the Meso Scale Discovery (MSD) platform, measure many cytokines with high sensitivity and a wide quantitative range from a small volume of culture supernatant.
- **Reporting:** report both absolute values and fold change.
- **Method status:** the assay should be qualified or validated.
- **Controls:** a positive control antibody known to cause clinical cytokine release (solid-phase OKT3 is a common choice), an unstimulated negative control, and an isotype control.

## Interpreting CRA data

No validated threshold yet defines a level of cytokine release that predicts clinical risk, so CRA cannot give precise safety predictions for a trial. It is used to flag products likely to cause severe release and to separate them from those that cause mild release. Benchmarking against known positive and negative antibodies helps show how a given format performs. Results should be read alongside target expression (location and level), mechanism of action, receptor occupancy, and the available pharmacology and toxicology data. Depending on how relevant and reliable the test system is, a positive or negative result can inform the starting dose and the dose-escalation design. Because CRS is clinically complex, extrapolating in vitro results to humans calls for great caution.

## What a positive result means

Current consensus is that a positive CRA should not by itself stop development. Experience with marketed products that cause cytokine release, such as OKT3, anti-thymocyte globulin, alemtuzumab (anti-CD52), and rituximab (anti-CD20), shows the risk can be managed. Options include changing the route (for example intravenous to subcutaneous), slowing the infusion rate, and premedication such as corticosteroids. Note that tumor lysis syndrome, a metabolic syndrome caused by rapid tumor cell death, causes hyperkalemia, hyperphosphatemia, hypocalcemia, uremia, and acute kidney injury, and is distinct from cytokine release.

Learn more about our [bioanalysis and biomarker services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers), or [contact us](https://www.crystalbiosolutions.com/contact-us) to discuss a cytokine release study.

## References

1. Goldman M, et al. OKT3-induced cytokine release attenuation by high-dose methylprednisolone. Lancet. 1989;2(8666):802–803.
2. Römer PS, et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood. 2011;118(26):6772–6782.
3. In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop. Cytokine. 2010;51:213–215.
4. Expert Group on Phase One Clinical Trials: Final Report (Chairman Professor Gordon Duff). 7 December 2006.
5. Stebbings R, et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol. 2007;179(5):3325–3331.
6. Findlay L, et al. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J Immunol Methods. 2010;352(1–2):1–12.
7. Grimaldi C, et al. Cytokine release: a workshop proceedings on the state-of-the-science, current challenges and future directions. Cytokine. 2016;85:101–108.
8. Vessillier S, et al. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials: whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm. J Immunol Methods. 2015;424:43–52.
9. Vessillier S, et al. Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms. Report of an international collaborative study. Cytokine X. 2020;2:100042.

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "CBS Marketing Team",
    "url" : "https://www.crystalbiosolutions.com/news-and-events/author/cbs-marketing-team"
  },
  "dateModified" : "2026-11-22T17:58:45.647Z",
  "datePublished" : "2026-11-22T17:58:45.000Z",
  "headline" : "In Vitro Cytokine Release Assays: Formats, Interpretation, and Limits",
  "image" : [ "https://www.crystalbiosolutions.com/hubfs/Microplate%20Inspection%20for%20Customized%20Assay%20Analysis.webp" ],
  "mainEntityOfPage" : {
    "@id" : "https://www.crystalbiosolutions.com/news-and-events/in-vitro-cytokine-release-assays-formats-interpretation-and-limits",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://www.crystalbiosolutions.com/hubfs/Crystal%20Bio%20Solutions%20logo.webp"
    },
    "name" : "Crystal Bio Solutions"
  }
}
```